Fluorescein Sodium And Benoxinate Hydrochloride is a drug owned by Bausch And Lomb Ireland Ltd. It is protected by 3 US drug patents filed from 2020 to 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Nov 15, 2037. Details of Fluorescein Sodium And Benoxinate Hydrochloride's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US10842872 | Fluorescein and benoxinate compositions |
Nov, 2037
(13 years from now) | Active |
| US10632197 | Fluorescein and benoxinate compositions |
Nov, 2037
(13 years from now) | Active |
| US10293047 | Fluorescein and benoxinate compositions |
Nov, 2037
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Fluorescein Sodium And Benoxinate Hydrochloride's patents.
Latest Legal Activities on Fluorescein Sodium And Benoxinate Hydrochloride's Patents
Given below is the list of recent legal activities going on the following patents of Fluorescein Sodium And Benoxinate Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Apr, 2024 | US10842872 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Sep, 2023 | US10632197 |
| Surcharge for Late Payment, Large Entity | 17 Jan, 2023 | US10293047 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jan, 2023 | US10293047 |
| Maintenance Fee Reminder Mailed Critical | 09 Jan, 2023 | US10293047 |
| Recordation of Patent Grant Mailed Critical | 24 Nov, 2020 | US10842872 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Nov, 2020 | US10842872 |
| Email Notification Critical | 05 Nov, 2020 | US10842872 |
| Issue Notification Mailed Critical | 04 Nov, 2020 | US10842872 |
| Dispatch to FDC | 27 Oct, 2020 | US10842872 |
US patents provide insights into the exclusivity only within the United States, but Fluorescein Sodium And Benoxinate Hydrochloride is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Fluorescein Sodium And Benoxinate Hydrochloride's family patents as well as insights into ongoing legal events on those patents.
Fluorescein Sodium And Benoxinate Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Fluorescein Sodium And Benoxinate Hydrochloride's generic launch date based on the expiry of its last outstanding patent is estimated to be Nov 15, 2037 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Fluorescein Sodium And Benoxinate Hydrochloride Generics:
There are no approved generic versions for Fluorescein Sodium And Benoxinate Hydrochloride as of now.
About Fluorescein Sodium And Benoxinate Hydrochloride
Fluorescein Sodium And Benoxinate Hydrochloride is a drug owned by Bausch And Lomb Ireland Ltd. It is used for facilitating ocular procedures and examinations in patients requiring a disclosing agent with a topical ophthalmic anesthetic. Fluorescein Sodium And Benoxinate Hydrochloride uses Benoxinate Hydrochloride; Fluorescein Sodium as an active ingredient. Fluorescein Sodium And Benoxinate Hydrochloride was launched by Bausch Lomb Ireland in 2020.
Approval Date:
Fluorescein Sodium And Benoxinate Hydrochloride was approved by FDA for market use on 09 March, 2020.
Active Ingredient:
Fluorescein Sodium And Benoxinate Hydrochloride uses Benoxinate Hydrochloride; Fluorescein Sodium as the active ingredient. Check out other Drugs and Companies using Benoxinate Hydrochloride; Fluorescein Sodium ingredient
Treatment:
Fluorescein Sodium And Benoxinate Hydrochloride is used for facilitating ocular procedures and examinations in patients requiring a disclosing agent with a topical ophthalmic anesthetic.
Dosage:
Fluorescein Sodium And Benoxinate Hydrochloride is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.4%;0.3% | SOLUTION/DROPS | Prescription | OPHTHALMIC |